VeriSIM Life February Newsletter

VeriSIM Life has been rolling right along through the start of ‘24 with events both recent and upcoming, as well as a new case study, media interviews and new content to share! Check out what we’ve been up to below, and as always, reach out if you would like to connect or have any questions.

Coming soon - 2024 Society of Toxicology Annual Meeting

This year’s SOT conference is happening in Salt Lake City, Utah next month and VeriSIM Life will be there! We’re eager to join leading toxicology experts from across the country, and are pleased to sponsor the 3Rs Collaborative’s AI Initiative meeting on 11-March, co-hosted at the conference. Planning to attend SOT? Let’s get a coffee and talk about toxicity ??!?

Recent Events - Italfarmaco Webinar & Westminster Health Forum?

At the end of January, CEO & Founder Dr. Jo Varshney led a webinar with Italfarmaco’s Dr. Grazia Rovelli, “AI and Drug Development - Keeping it Real with Pharma.” The event was an illuminating discussion on topics such as the paramount importance of trust in adopting AI technology, how to measure success when rolling out such a program and more. View the webinar, or browse the transcript.?

Earlier in the month, Dr. Varshney spoke on a panel at the Westminster Health Forum, “Priorities and next steps for tackling antimicrobial resistance in the UK.” The event was described as “a timely opportunity for stakeholders and policymakers to examine priorities for the new AMR action plan expected next year, with the current 5-year action plan coming to an end.” Watch the recording of the entire forum and access additional conference materials.?

Case Study: Predicting Translatable Drug Combinations for ADCs??

VeriSIM Life investigated for our client Debiopharm a novel drug combination strategy that combines ADCs with current therapies to enhance their effectiveness in reducing tumor burden. In this case study, our hybrid AI computational platform, BIOiSIM?, ranked the predicted optimal combinations with regard to efficacy based on our multi-dimensional Translational Index? technology, leading the client to success.?Read it now.

Q&A’s with Dr. Jo Varshney in Infection Control Today & CIO.inc

“My biggest advice would be to invest in AI today. Now is the right time to embed AI into your drug development processes to make them more cost- and time-efficient,” writes Dr. Jo Varshney in this Q&A article in Infection Control today, “AI-Driven Predictive Analytics: Transforming Drug Development.”?

“I appreciate that organizations that are not ‘AI-native’ can be reticent to adopt AI techniques, and employees are often resistant to leverage it, perceiving their jobs could be threatened by AI replacement. But leveraging AI is about adapting to change, which we’ve embraced in business for decades,” she explains.

Prefer a video Q&A instead? Dr. Varshney was also featured in this piece by CIO.inc, “The Role of AI and ML in Clinical Testing of New Drugs” - check it out to hear her explain the Translational Index and its impact on drug development, with special emphasis on patient stratification.

Blog: Crash Course to Using AI to Determine Dose Selection

The development of a drug is a complex and lengthy process, requiring precise decisions about dosing to ensure both the efficacy and safety of a drug. Luckily, AI can be used for dose selection in drug development—helping to save time, money, and increase accuracy. Before embarking upon this journey, it is important to grasp not only the basics of dose selection and why it’s important in drug development, but also how exactly AI improves the dose selection process. Then, once you understand these core concepts, you can begin evaluating various AI-based solutions for your specific needs. Check out the blog post for the full guide.

Life Science Trends to Look Out for in 2024

Our mission at VeriSIM Life is to meaningfully impact the lives of patients with unmet needs by improving the success of our clients’ science in the clinic. But another key goal is to reduce unnecessary animal experimentation along the way. This article in Financial Times, in which VeriSIM Life was mentioned, reviews the ways AI could help end animal testing by pharma companies.?

Love for AI in Drug Discovery & Development ??

We’re in the Valentine’s Day spirit, here in the United States. So we wanted to list out just a few of the reasons why AI deserves so much love in the quest to get quality treatments to patients, faster.

• It can help across a wide array of solution areas, from patient stratification to safety-toxicity profiles, dose optimization and beyond.?
• It saves clients millions of dollars and shortens the amount of time to market for a drug candidate - see just a few success stories here!
• It can seriously de-risk R&D decisions, saving millions of dollars and multiple years that would have been wasted using traditional methods of development & discovery alone.
• As mentioned before, it can aid in reducing the need for using animals in clinical testing.

Those are just a few of myriad reasons for you to consider integrating AI into your drug development strategy. Curious on how to start? Check out our eBook, How to Evolve from Traditional Model-Informed Drug Discovery & Development to an AI-Informed Approach, to learn more - or set up a demo with our team!